


2023 Texas Dermatological Society

Spring Meeting Brochure + Member News

A photograph of the Austin skyline at night, with the city lights reflecting on the water. The image is framed by white, overlapping circular lines that create a sense of depth and movement.

Austin

April 28 - 29, 2023

**Hyatt Regency Austin Downtown
Austin, TX**

**10 AMA PRA category 1 Credits™,
including 1 hour of Ethics**

[REGISTRATION FORM ON PAGE 8](#)

*Educational Program jointly sponsored by
Texas Medical Association and the
Texas Dermatological Society*



Thank you to our local hosts Dr. Jennifer Ruth, Dr. Khang Nguyen and UT Austin Dell for developing the CME program and meeting events.



TDS loves our Exhibitors and Sponsors!

EXHIBIT HALL HOURS

Friday

11:00 am - 3:00 pm

Saturday

7:00am - 3:30pm

Welcome Reception

5:00pm - 6:00pm

Please take time to visit our exhibitors as they help keep costs low for attendees.

TDS will host door prize drawings for those of you who visit the exhibitors. Winners will be announced at the business lunch on Saturday.

Support Your Future Partner

To encourage resident attendance TDS offers housing stipends to offset the travel and lodging costs for residents to attend the meeting. Please consider donating \$25 to this fund. Donors will be acknowledged in the onsite handout and TDS newsletter.

Target Audience

The target audience is dermatologists, dermatological surgeons, pediatric dermatologists and residents in dermatology. Educational Methods used will include lectures, Q&A sessions, and case presentations.

Business Meeting/Change of Officers


Everyone is welcome to attend the business meeting but only Active, Associate, Affiliate, Honorary and Life Members of TDS may vote. The business luncheon will be held on Saturday.

Special Considerations

We do try to control the temperature in the meeting room, but for your comfort, please bring a jacket.

CME Requirements Have Changed!

Attendees now need to "OPT IN" to allow exhibitors and sponsors to receive names/office addresses as a handout. These handouts are crucial for exhibitors to show value to their companies. Please check the box to "OPT IN" to this list on the registration form. This list is something we have given exhibitors every year in the past, you will not receive any additional mail than you have in the past by checking the box.



Hyatt Regency Austin

208 Barton Springs Rd
Austin, TX, 78704

Reservations: Call (512) 477-1234 or click to [register online](#).

TDS Room Rate: \$219/night plus taxes

Parking: Discounted \$25/night self-parking in their garage

TDS has a room rate of \$219, room rate does not include taxes. Be sure to mention you are with Texas Dermatological Society. Make your reservation by April 6, 2023 to receive this rate, or, until room-block is full.

Did You Know...?

TDS contracts with a host hotel each year, promising a minimum number of sleeping rooms to the hotel. In return, the hotel offers the complimentary or reduced meeting room and other services that make the TDS meeting so successful. By booking your room at the Hyatt Regency Austin, you help keep registration costs and membership dues low.

Registration

Advance registration for the meeting and for all social events is important. The deadline for early bird registration is April 18th. To ensure participation in social events and meal functions. TDS must receive notice of cancellation for refund postmarked no later than April 18th. A fee will be deducted from the registration fee paid to cover processing charges. Non-attendance does not constitute notice of cancellation.

Pre-Registration for the conference will close Tuesday, April 18th. Any registrations after April 18th will be on-site at the Hyatt Regency.



Virtual Option

For members uncomfortable meeting in-person or who can't travel, the TDS will be live-streaming the general session of the conference. Please be sure to select the "virtual" registration option on the registration page. The link for the live-stream will be emailed out to virtual attendees the week of the meeting.

For those members who chose the virtual option, you **MUST** attend the live-stream general session lectures at the time of their talks to obtain CME for the conference. CME cannot be given for lectures viewed post-conference.

If you are attending in-person at the Hyatt Regency, the recorded lectures will be available for viewing and review a few weeks post-conference.

Schedule

Friday, April 28, 2023

7:00 a.m.

Exhibitor Check-In and Breakfast

8:00 a.m. – 11:00 a.m.

TDS Board of Directors Meeting

11:00 a.m. – 1:00 p.m.

TDS Academic Leadership Symposium and Luncheon

11:00 a.m. – 1:00 p.m.

TDS Resident Lunch and Round Table Discussion

11:00 a.m. – 1:00 p.m.

TDS Member Lunch with Exhibitors

1:00 p.m. – 2:30 p.m.

Welcome & TDS Resident Podium Presentations

2:30 p.m. – 3:00 p.m.

Break with Exhibitors & Poster Viewing

3:00 p.m. – 4:00 p.m.

Innovation in Dermatologic Surgery
Chris Miller, MD

4:00 p.m. – 4:30 p.m.

Updates in Dermatologic Medicines
Adam Olesen, MD

4:30 pm – 5:00 p.m.

Mohs Surgery for Melanoma
Tyler Hollmig, MD

5:00 p.m. – 6:00 p.m.

TDS Reception – Sponsored by SAGIS

6:00 p.m. – 9:00 p.m.

TDS 1st Annual Resident Challenge Bowl

Saturday, April 29, 2023

7:00 a.m. – 8:00 a.m.

TDS Member Breakfast with Exhibitors

8:00 a.m. – 9:30 a.m.

Patient Case Presentations

9:30 a.m. – 10:00 a.m.

Break with Exhibitors

10:00 a.m. – 11:00 a.m.

How Deep Knowledge of Anatomy Can Transform Dermatology
Chris Miller, MD

11:00 a.m. – 12:00 p.m.

Artificial Intelligence in Dermatology
Adewole Adamson, MD

12:00 p.m. – 12:50 p.m.

TDS Member Business Lunch

1:00 p.m. – 2:00 p.m.

Management of Psoriasis in Pediatric Patients
Amy Paller, MD

2:00 p.m. – 3:00 p.m.

New JAK Inhibitors in Dermatology
Amy Paller, MD

3:00 p.m. – 3:30 p.m.

Break with Exhibitors

3:30 p.m. – 4:30 p.m.

ETHICS CREDIT - Managing Difficult Patients
Michelle Magid, MD
Jason Reichenberg, MD

4:30 p.m.

ADJOURN



**NEW THIS YEAR! 1st Annual
TDS Resident Challenge Bowl**
Friday, April 28th

Sponsored by SAGIS

The TDS will be hosting the
1st annual TDS Resident Challenge Bowl,
at the Spring 2023 meeting!
The challenge bowl will take
place the evening of Friday, April 28th
at the Hyatt Regency in Austin.

Keep your eyes open for more information
to come in the next month!

Welcome Our New TDS Members!

Active Members

Ashwin Agarwal, MD, Plano
Tara Akunna, MD, Houston
Aaron Solomon Farberg, MD, Dallas
Betsy Furukawa, Temple
Meghan Mcintosh Heberton, MD, Houston
Jorge A. Hinojosa, MD, Dallas
Auris O. Huen, MD, Houston
Rachelle Lou Naridze, MD, Pflugerville

Allied Health Members

Amy Jones, PA-C, Plano
Lindsay Weber, PA-C, Austin

Resident Members

Ryan A. Ball, MD, Plano
Jonathan Banta, MD, San Antonio
Ashley E. Brown, MD, Houston
Diane A. Fernandes, MD, Lackland AFB
Mary B. Gadarowski, MD, San Antonio
Yizhen E. Martin, MD, Lackland AFB
Momina Mazhar, MD, Dallas

See You at the Capitol TDS 2023 ADVOCACY EVENTS

February 22, 2023

TDS ADVOCACY CONFERENCE AT THE CAPITOL

The TDS will hold its 1st annual Advocacy Conference at the Texas State Capitol on 2/22/2023. We need TDS members to attend this event to help represent all dermatologists and to be the voice of dermatologic legislative priorities in Texas. Eric Woomer, TDS lobbyist, and his team will lead the day's efforts. There will be a virtual training prior to 2/22/2023 to help guide participants for what to expect from an advocacy day; review TDS' legislative priorities; set schedules and expectations for day-of; and answer any questions. Members should plan on blocking their entire day on 2/22/2023 to participate. More information will be forthcoming. We need volunteers – if you are interested in participating, please [CLICK HERE](#) or email Laura Madole at laura.madole@texmed.org.

March 1, 2023

TDS SKIN CANCER SCREENING AT THE CAPITOL

TDS is proud to announce our 3rd Capitol Skin Cancer Screening Day at the Texas State Capitol from 1PM - 3PM on 3/1/2023. The format will be similar to previous years, and we will need 4-5 TDS physician member volunteers to screen Legislators and staff. There will be partitioned rooms and all forms and materials will be provided on-site through the AAD skin cancer screening committee. This event has been well-received and attended in previous years, so we look forward to a successful screening and awareness day. More information will be forthcoming. If you're able to participate in this important event, please [CLICK HERE](#) or email Laura Madole at laura.madole@texmed.org.

Hey Residents!

Resident Housing Stipend

The TDS offers a generous housing stipend to all Texas residents who are current TDS members who attend the meeting. Each resident who applies for the stipend will be presented with a housing stipend reimbursement form upon check in. This form should be filled out and returned to the TDS registration table on-site or business office within a week of the meeting. Each resident will have one night reimbursed in host hotel, or an equivalent hotel. Only current Texas residents who are TDS members can apply for and receive the stipend.

- Residents who reside in the host city are not eligible for the stipend.
- The TDS will only reimburse for one night hotel rate, applicable taxes, resort fee (if applicable) and self parking. If valet parking/food/extra charges are submitted for reimbursement, The TDS will deduct the appropriate amount and reimburse only for eligible expenses.

Resident Lunch

Your co-resident reps to the board wanted to get the group together this spring for a resident lunch. Please join your fellow TDS residents on April 28th from 11:00 am - 12:30pm for a great lunch and open Q&A discussion.

Hope to see you there! Please encourage all of your fellow residents to join the TDS - it's FREE!

TDS Fall 2023 Abstract Competition!

FRIDAY, APRIL 28TH

Residents, Fellows & Medical Students will have the opportunity to present their abstracts and research in two different settings:

PODIUM COMPETITION

Application Deadline: March 27, 2023

Abstract Paragraph & Video Presentation: April 3, 2023

The resident podium competition will take place from 1:00-2:30pm on Friday April 28th. The residents competition in this competition will be up for one of the three awards listed below.

POSTER COMPETITION

Application Deadline: March 27, 2023

Abstract Paragraph & Poster PDF Deadline: April 3, 2023

The resident poster competition will take place all day Friday, April 28th. The posters will be judged throughout the day on Friday. You do not have to be present to win.

POSTER AND PODIUM COMPETITION FAQs

- ✓ Please see www.texasdermatology.org and click "Residents' Corner" for detailed guidelines and the application via SurveyMonkey.
- ✓ Residents are only eligible to win. Medical Students and Fellows are welcome to participate.
- ✓ Winners will be announced on Saturday, April 29th during the business lunch.
- ✓ Prizes will be awarded for 1st, 2nd, and 3rd place in the amounts of \$500, \$300 and \$200 as well as certificates.
- ✓ Questions? Aliza Gersh, Meeting Coordinator
Aliza.Gersh@texmed.org



TDS is active on social media

Follow us today to keep up with the latest trending news for Texas Dermatologists!



@texasderms



@txderms

Keep us posted! Send news of your recent appointments, accomplishments, announcements, etc. We are unable to reprint abstracts or published articles; however, we will list the citation of any articles that were published in a peer-reviewed journal. Send information to Laura.Madole@texmed.org.

Thank You!

THANK YOU TO OUR SPONSORS & EXHIBITORS

PLATINUM



GOLD

AbbVie

SILVER

Ortho Dermatologics a Div of Bausch Health

EXHIBITORS

Baylor Scott & White Health

Clinical Pathology Associates

Cockerell Dermatopathology

DermCare Management

Huffman Builders

Mallinckrodt

SkinCure Oncology

South Texas Dermatopathology/ProPath

Xstrahl, Inc.

Accreditation

This activity has been planned and implemented in accordance with Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Texas Medical Association and the Texas Dermatological Society. Texas Medical Association is accredited by the ACCME to provide continuing medical education for physicians.

Texas Medical Association designates this educational activity for a maximum of 10 *AMA PRA category 1 Credits™*, including 1 hour of Ethics. "Managing Difficult Patients" (from 3:30pm - 4:30pm on Saturday, April 29th) has been approved for 1 hour ethics credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

REGISTRATION FORM – PLEASE REGISTER ONLINE

Save by registering early! Your registration fee includes CME fees, food, functions, handouts, and access to the Welcome Reception.

Please contact **Aliza Gersh**, Meeting Coordinator at aliza.gersh@texmed.org.

(Please Print or Type)

☐ IN-PERSON ☐ VIRTUAL

Name: _____

Address: _____ City/State/Zip: _____

Phone: _____ Fax: _____

Email *: _____

*CME information will be sent by email and must be submitted online.

Contact person & phone number in case of on-site emergency: _____

***Cancellation Policy:** TDS must receive notice of cancellation for refund postmarked no later than April 18, 2023. A \$25 fee will be deducted from the registration fee paid to cover processing charges. Non-attendance does not constitute notice of cancellation. Registration Deadline: April 18, 2023.

New Member - 1st Meeting

Registration for Members

Member
Honorary Member
Resident Member
Speaker

	\$0		\$0	
	BY APRIL 18		AFTER APRIL 18	
	In-Person	Virtual	In-Person	Virtual
Member	\$150	\$150	\$200	\$200
Honorary Member	\$50	\$50	\$50	\$50
Resident Member	\$0	\$0	\$50	\$50
Speaker	\$0	\$0	\$0	\$0

Registration for Non-Members

Non-Member
Non-Member Resident
Allied Health Professional

☐ Special offer for non-members!

To take advantage of this offer, check the box to the left and include \$300 as your registration fee. This will pay your member CME registration and your TDS membership thru 12/31/2023.

*For Residents check the box to the left and include \$0 (early)/\$50 (late/onsite) as your registration fee. You will be contacted after the conference if more information is needed to complete your membership profile.

Events

- ☐ Friday: Resident Challenge Bowl @ no charge
☐ Friday: Welcome Reception @ no charge
☐ **Please OPT-IN here to have no changes** made to the method in which you receive exhibit/sponsor/conference handout information"

Meal Attendance

Friday, 4/28 ☐ Resident Lunch ☐ Member Lunch ☐ Welcome Reception
 Saturday, 4/29 ☐ Member Breakfast ☐ Member Business Lunch

Grand Total: _____

Payment Information

Enclosed is a check for \$ _____ (Make checks payable to **Texas Dermatological Society**)

Please charge my credit card

- ☐ Credit Card – Register online at www.texasdermatology.org or call TDS at 512-370-1502 to pay over the phone
☐ Check Enclosed (payable to Texas Dermatology Society)

Mail this form and payment to: Texas Dermatological Society, 401 W. 15th St., Suite 100, Austin, TX 78701

*There will be a \$25 service fee to switch your registration option virtual to live, or vice versa after your original selection

CME REQUIREMENTS HAVE CHANGED! Attendees now need to "OPT IN" to allow exhibitors and sponsors to receive names/office addresses as a handout. These handouts are crucial for exhibitors to show value to their companies. Please check the box to "OPT IN" to this list on the registration form. This list is something we have given exhibitors every year in the past, you will not receive any additional mail than you have in the past by checking the box.

Please mail registration to:

Texas Dermatological Society
401 W. 15th St., Suite 100
Austin, TX 78701



Congratulations!

To the Winners of the 2022 Annual Fall Meeting Resident Podium and Poster Competitions

Below are the winning abstracts

PODIUM WINNERS

1st Place

Jamael Lamb Thomas, MD, MPH – UT Houston

[Differential CD4+ T cell cytokine and cytotoxic responses between reactivation and latent phases of herpes zoster](#)

Jamael Thomas¹ ; Susuana Adjei, MD² ; Laurie A. Temiz, BA³ ; Stephen K. Tying, MD, PhD^{1,2} ¹UT Health Science Center, Houston, TX, ²Center for Clinical Studies, Houston, TX, ³Meharry Medical College, Nashville, TN

CD4+ T cells are a critical component of effective immune responses to varicella zoster virus (VZV), but their functional properties during the reactivation acute vs. latent phase of infection remain poorly defined. Here we assessed the functional and transcriptomic properties of peripheral blood CD4+ T cells in persons with acute herpes zoster (HZ) compared to those with a prior history of HZ infection. We found significant differences between the polyfunctionality of total and VZV-specific total memory, effector memory, and central memory CD4 T cells in acute vs prior HZ. VZV-specific CD4+ memory T cell responses in acute HZ reactivation had higher frequencies of IFN- γ and IL-2 producing cells compared to those with prior HZ. In addition, cytotoxic CD4 markers were present more in VZV-specific T cells than other T cells in acute and prior HZ individuals. Transcriptomic analysis of ex vivo total memory CD4 T cells from these individuals showed differential regulation of T cell survival and differentiation pathways, including TCR, CTL, T helper, inflammation and MTOR signaling pathways. These gene signatures correlated with the frequency of IFN- γ and IL-2 producing cells responding to VZV with linear regression analysis. In summary, VZV-specific CD4 T cells from acute HZ individuals had unique functional and transcriptomic features

2nd Place

Corley Pruneda, MD – TTUHSC

[A novel and minimally invasive treatment of an angioleiomyoma of the nose](#)

3rd Place

Priscilla Kojder, MD – UT Austin Dell Medical School

[A Focused Educational Module as an Effective Tool for Improving Diagnostic Accuracy in Skin of Color](#)

Priscilla Ly Kojder, MD¹ , Catherine Pisano, MD¹ , Maria Leszczynska, MD² , Ashley Riddle, MD¹ , Lucia Diaz, MD^{1, 2} , Ammar M Ahmed, MD¹ ¹ Department of Internal Medicine, Division of Dermatology, Austin TX ² Dell Medical School, Department of Pediatrics, Division of Pediatric Dermatology, Austin, TX

Dermatologic disparities disproportionately affect patients with skin of color (SoC). This study evaluates the effectiveness of a focused educational module for improving diagnostic accuracy and confidence in treating SoC among interprofessional healthcare providers. A SoC educational module involving a pre-test, 15-minute lecture, immediate post-test, and 3-month post-test was created. One hundred subjects completed the pre-and immediate post-test, of whom 36 completed the 3-month post-test. Overall, pre-test diagnostic accuracy was higher for skin conditions shown on light skin compared to dark skin (13.6 vs 11.3, $p < 0.001$). Within subgroups, pre-test diagnostic accuracy was higher for skin conditions shown on light skin compared to dark skin for cancerous, inflammatory, and infectious conditions (72% vs 75%; $p = 0.059$). Controlling for provider type and specialty, diagnostic accuracy improved for conditions shown in light and dark skin types immediately following the intervention (13.6 vs 15.2, $p < 0.001$; 11.3 vs 13.3, $p < 0.001$).

Improvement remained significant only for conditions shown on dark skin at three-months post-intervention

(continued)

2022 Annual Fall Meeting Resident Podium and Poster Competitions

(11.3 vs 13.3, $p < 0.01$). Our study shows that diagnostic disparities between light and dark skin exist among interprofessional providers, specifically affecting infectious, cancerous or inflammatory conditions more commonly than conditions that are preferentially seen in SoC. A focused educational module may provide long-term improvements in confidence and diagnostic accuracy for conditions portrayed in SoC.

POSTER WINNERS

1st Place

Tayler Parker, MD – UT Houston

Selinexor Modulation of the Sterol Regulatory Element Binding Proteins and Lipogenic Enzymes in the Lipid Metabolism of Merkel Cell Carcinoma Cell Lines

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that is etiologically linked to the Merkel cell polyomavirus (MCPyV). The first-line therapy for MCC is immunotherapy, however, current studies demonstrate that immunotherapy produces an objective response in just over half of patients, with nearly one in five experiencing a treatment related adverse event. Selinexor (KPT-330) is a novel selective inhibitor of nuclear transport (SINE) that binds the exportin receptor, XPO1, in cancer cells. The inhibition of XPO1 prevents the transfer of tumor suppressor proteins (TSPs) and oncoprotein mRNAs out of the cell, causing cell cycle arrest and apoptosis. Previous research in our lab demonstrates that selinexor exhibits a dose-dependent reduction of MCC biomarkers, DNA damage response proteins, and carcinogenic viral large and small T antigens in MCC in vitro. This study evaluates the effect of increasing doses of selinexor on lipid biosynthesis pathways in MCC cell lines. Cancer cells notoriously upregulate transcription factors and enzymes involved in the fatty acid and cholesterol biosynthesis. The increase in lipids allows cancer cells to produce the phospholipids necessary for uncontrolled cell proliferation and form signaling molecules involved in carcinogenesis. Selinexor causes highly statistically significant reductions ($p < 0.01$) in the proteins of the fatty acid synthesis pathway: SREBP1, ACC, and FASN, and in the cholesterol synthesis pathway: SREBP2, SQS, and DHCR24 in MKL-1 cell lines. In the MS-1 cell lines, selinexor exhibits highly statistically significant reductions in SREBP1, SREBP2, SQS, and DHCR24 and statistically significant reductions ($p < 0.05$) in ACC and FASN. These results reveal an additional

pathway by which selinexor may exert its anticancer effects. Selinexor may provide clinical benefit for patients with immunotherapy-refractory MCC. Further investigation of selinexor in in vivo studies is warranted.

2nd Place

Caroline Starling, MD – UT Houston

Treatment of refractory cutaneous B-cell pseudolymphoma with intralesional rituximab

Caroline Starling^{1,3}, MD, Areebah Ahmad², BA, Meghan Heberton³, MD ¹ Department of Dermatology, The University of Texas Health Science Center at Houston, Texas ² McGovern Medical School, The University of Texas Health Science Center at Houston, Texas ³ Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas

A 61-year-old woman without significant medical history presented with four years of persistent dermal plaques of the bilateral lower eyelid margins and bilateral cheeks. Previous biopsy of the left lower eyelid showed atypical B-cell lymphoid infiltrate. Past treatments included three excisions, topical steroids, intralesional steroids, radiation to the eyelids (4 Gy), and hydroxychloroquine. Patch testing was positive for tixocortol-21-pivalate. Punch biopsy of the left cheek showed a dense dermal lymphoid B-cell infiltrate associated with reactive lymphoid follicles. Additional studies with immunoglobulin heavy chain gene rearrangement polymerase chain reaction showed a polyclonal B-cell population with no molecular support for the presence of a B-cell lymphoma. Complete blood count and comprehensive metabolic panel were normal. Human immunodeficiency virus, Hepatitis B and C, T-spot, and borrelia antibodies were negative. Positron emission tomography-computed tomography showed hypermetabolic activity of the skin on the left cheek and bilateral lower eyelids only. A diagnosis of cutaneous B-cell pseudolymphoma was given. Methotrexate was prescribed at 15 mg weekly without improvement. Systemic rituximab was discussed and declined by the patient out of concern for immunosuppression during the Covid-19 pandemic. Intralesional rituximab injections to the plaques on the cheeks were initiated. She received four cycles of four weekly 10-30 mg injections over one year.

(continued)

2022 Annual Fall Meeting Resident Podium and Poster Competitions

She experienced a marked decrease in the size and thickness of the plaques as well as pruritus. She had no systemic side effects and tolerated the treatments well. This case highlights the potential utility of intralesional rituximab for refractory cutaneous B-cell pseudolymphoma.

3rd Place

Quac-Bao Nguyen, MD – UT Houston

Tips for Auricular Cartilage Harvesting using the Posterior Approach

Quoc-Bao Nguyen MD MBA,1,2 Deborah Watson MD3

1. Department of Dermatology, UTHealth McGovern Medical School, Houston, TX 2. Department of Dermatology, MD Anderson Cancer Center, Houston, TX 3. Department of Otolaryngology-Head and Neck Surgery, University of California-San Diego, School of Medicine

Small defects of the nasal ala are not uncommon after Mohs extirpation. When the defect is deep enough to compromise the three-dimensional stability of the alar rim, cartilage grafts provide structural support of the alar lobular tissue as well as satisfactory

aesthetic and functional outcomes. The auricle is an excellent donor source for cartilage grafts used for nasal reconstruction because it provides contoured cartilage grafts. Certain regions of the auricle can replicate the convex topography of the nasal ala and alar rim. The authors recommend the harvest of conchal cartilage as the preferred location. One of the goals for auricular cartilage harvesting is to obtain a cartilage graft with sufficient width and length for reconstructive purposes while preserving the natural contours of the ear. Auricular cartilage from the conchal bowl can be harvested either by a posterior or an anterior approach. However, the posterior approach has an added benefit of concealing the incisional scar behind the ear compared to the anterior approach. Popular belief has supported the practice of the anterior approach to the conchal bowl cartilage because of reported access to a greater amount of cartilage while preservation of the contours of the ear. Herein, the authors describe and illustrate the technical pearls to facilitate using the posterior approach for scar concealment while harvesting adequate width and length of conchal cartilage, and preserving the auricle shape.

Save the Dates!



2023 Annual Fall Meeting

Sept. 22-23 | San Antonio, TX
The Hyatt Hill Country Resort and Spa



2024 Annual Spring Meeting

April 19-20 | Houston, TX
Marriott Marquis

Recent TDS Member Articles & Publications

[Reducing anxiety and preventing trauma in pediatric epidermolysis bullosa.](#)

Haller CN, Jaquez SD, Henkel ED, Levy ML, Diaz LZ.
 Pediatr Dermatol. 2022 May;39(3):497-501. doi: 10.1111/pde.14951. Epub 2022 Mar 1.
 PMID: 35229902

[Caregiver Preferences and Barriers Toward Accessing Pediatric Dermatology Care for Childhood Atopic Dermatitis.](#)

Croce EA, Rathouz PJ, Lopes FCPS, Leszczynska M, Diaz LZ, Levy ML, Ruth JS, Varshney P, Rew L, Matsui EC.
 J Pediatr Health Care. 2022 Jul-Aug;36(4):e1-e5. doi: 10.1016/j.pedhc.2022.04.003. Epub 2022 May 5.
 PMID: 35527176

[A retrospective analysis of diagnostic testing in a large North American cohort of patients with epidermolysis bullosa.](#)

Phillips GS, Huang A, Augsburger BD, Kaplan L, Peoples K, Bruckner AL, Khuu P, Tang JY, Lara-Corrales I, Pope E, Wiss K, Levin LE, Morel KD, Hook KP, Paller AS, Eichenfield LF, McCuaig CC, Powell J, Castelo-Soccio L, Levy ML, Price HN, Schachner LA, Browning JC, Jahnke M, Shwayder T, Bayliss S, Lucky AW, Glick SA.
 J Am Acad Dermatol. 2022 May;86(5):1063-1071. doi: 10.1016/j.jaad.2021.09.065. Epub 2021 Oct 8.
 PMID: 34634382

[The New Face of Preadolescent and Adolescent Acne: Beyond the Guidelines.](#)

Eichenfield L, Hebert A, Desai SR, Levy ML, Mancini AJ, Rice ZP, Sugarman J, Zaenglein A.
 J Fam Pract. 2022 Jul;71(6 Suppl):S63-S70. doi: 10.12788/jfp.0430.
 PMID: 35960938

[Gastrostomy tube feeding in epidermolysis bullosa: A multi-center assessment of caregiver satisfaction.](#)

Kleinman EP, Reimer-Taschenbrecker A, Haller CN, Paller AS, Levy ML, Eichenfield LF.
 Pediatr Dermatol. 2022 Dec 3. doi: 10.1111/pde.15207.
 Online ahead of print.
 PMID: 36461900

regularly with representatives of various payers, such as Aetna, UHC Humana and others. If you encounter claim denials or payment issues feel free to reach out to Ryan (ryan.hick@propath.com) or the AAD PAPRC staff.

[Antimicrobials and resistance part II: Antifungals, antivirals, and antiparasitics.](#)

Muhaj FF, George SJ, Nguyen CD, Tyring SK.
 J Am Acad Dermatol. 2022 Jun;86(6):1207-1226. doi: 10.1016/j.jaad.2021.11.065. Epub 2022 Feb 2.
 PMID: 35122895 Review.

[Bacterial antimicrobial resistance and dermatological ramifications.](#)

Muhaj FF, George SJ, Tyring SK.
 Br J Dermatol. 2022 Jul;187(1):12-20. doi: 10.1111/bjd.21033.
 Epub 2022 Apr 12.
 PMID: 35083740 Review.

[Part I Antimicrobial resistance: Bacterial pathogens of dermatologic significance and implications of rising resistance.](#)

George S, Muhaj FF, Nguyen CD, Tyring SK.
 J Am Acad Dermatol. 2022 Jun;86(6):1189-1204. doi: 10.1016/j.jaad.2021.11.066. Epub 2022 Feb 2.
 PMID: 35122894 Review.

[Response to Chu et al's "Developing and implementing approaches to limit antimicrobial resistance".](#)

Muhaj FF, Tyring SK.
 J Am Acad Dermatol. 2022 Aug 20:S0190-9622(22)02426-4. doi: 10.1016/j.jaad.2022.07.052. Online ahead of print.
 PMID: 35998840

[Eosinophilic homogeneous intracytoplasmic inclusion bodies: Unique viral cytopathic changes associated with epidermodysplasia verruciformis and human papillomavirus type 49.](#)

Bartley BR, Huen A, Rady PL, Tyring SK, Nagarajan P, Aung PP, Curry JL, Ivan D, Torres-Cabala CA, Prieto VG, Cho WC.
 J Cutan Pathol. 2022 Jul;49(7):658-662. doi: 10.1111/cup.14221. Epub 2022 Mar 21.
 PMID: 35262953

Ryan Hick has been appointed to serve as the deputy chair of the Patient Access Payer Relations Committee of the American Academy of Dermatology. In this assignment, along with Dr. Mollie MacCormack and AAD staff he meets

(continued)

Recent TDS Member Articles & Publications

[Condyloma and coincidental epidermodysplasia verruciformis acanthoma positive for human papillomavirus-14 and -21.](#)

Bartley B, Cho WC, Rady PL, Dai J, Curry JL, Milbourne A, Tying SK, Torres-Cabala CA.
J Cutan Pathol. 2022 Aug 30. doi: 10.1111/cup.14319.
Online ahead of print.
PMID: 36039682

[Antibiotic resistance in dermatology: The scope of the problem and strategies to address it.](#)

Shah RA, Hsu JI, Patel RR, Mui UN, Tying SK.
J Am Acad Dermatol. 2022 Jun;86(6):1337-1345. doi: 10.1016/j.jaad.2021.09.024. Epub 2021 Sep 20.
PMID: 34555484 Review.

[The efficacy of selinexor \(KPT-330\), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.](#)

Landes JR, Moore SA, Bartley BR, Doan HQ, Rady PL, Tying SK.
J Cancer Res Clin Oncol. 2022 Aug 8. doi: 10.1007/s00432-022-04247-z. Online ahead of print.
PMID: 35941226 Review.

[Molecular evidence for selinexor as a treatment for Merkel cell polyomavirus \(MCPyV\)-positive Merkel cell carcinoma.](#)

Bartley BR, Simonette RA, Rady PL, Doan HQ, Tying SK.
Int J Dermatol. 2022 Jan 30. doi: 10.1111/ijd.16057. Online ahead of print.
PMID: 35094380 No abstract available.

[Selinexor is a novel inhibitor of DNA damage response in Merkel cell carcinoma.](#)

Moore SA, Narayanan D, Simonette RA, Bartley BR, Doan HQ, Rady PL, Tying SK.
Clin Exp Dermatol. 2022 Jul;47(7):1354-1357. doi: 10.1111/ced.15120. Epub 2022 Mar 16.
PMID: 35120268

[Tirbanibulin 1% ointment eradicates HPV-16 \(+\) vulvar high-grade squamous intraepithelial lesion.](#)

Moore AY, Moore SA, He Q, Rady P, Tying SK.
J Eur Acad Dermatol Venereol. 2022; 36(10):e784-e785. doi: 10.1111/jdv.18265. Epub 2022 Jun 7.
PMID: 35608184 No abstract available.

[Human papillomavirus 57 positivity in periungual squamous cell carcinoma eradicated by topical tirbanibulin.](#)

Moore AY, Moore SA, He Q, Rady P, Tying SK.
JAAD Case Rep. 2022; 22:58-59. doi: 10.1016/j.jdc.2022.01.021. eCollection 2022 Apr.
PMID: 35340732 Free PMC article. No abstract available.

[Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial.](#)

Sigurgeirsson B, Browning J, Tying S, Szepietowski JC, Rivera-Díaz R, Effendy I, Keefe D, Bruin G, Paguet B, Fu R, Hampele I, Reinhardt M, Patekar M.
Dermatol Ther. 2022;35(3):e15285. doi: 10.1111/dth.15285.
Epub 2022 Jan 8.
PMID: 34954841 Clinical Trial.

[One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial.](#)

Strober B, Stein Gold L, Bissonnette R, Armstrong AW, Kircik L, Tying SK, Piscitelli SC, Brown PM, Rubenstein DS, Tallman AM, Lebwohl MG.
J Am Acad Dermatol. 2022 Oct;87(4):800-806. doi: 10.1016/j.jaad.2022.06.1171. Epub 2022 Jun 27.
PMID: 35772599

[Zoster-associated Prothrombotic Plasma Exosomes and Increased Stroke Risk.](#)

Bubak AN, Coughlan C, Posey J, Saviola AJ, Niemeyer CS, Lewis SWR, Lopez SB, Solano A, Tying SK, Delaney C, Neeves KB, Mahalingam R, Hansen KC, Nagel MA.
J Infect Dis. 2022 Oct 6;jiac405. doi: 10.1093/infdis/jiac405. Online ahead of print.
PMID: 36200236

[Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota.](#)

Ghannoum MA, Long L, Bunick CG, Del Rosso JQ, Gamal A, Tying SK, McCormick TS, Grada A.
Antibiotics (Basel). 2022;11(3):324. doi: 10.3390/antibiotics11030324.
PMID: 35326788

[Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial.](#)

Gelfand JM, Shin DB, Armstrong AW, Tying SK, Blauvelt A, Gottlieb S, Lockshin BN, Kalb RE, Fitzsimmons R, Rodante J, Parel P, Manyak GA, Mendelsohn L, Noe MH, Papadopoulos M, Syed MN, Werner TJ, Wan J, Playford MP, Alavi A, Mehta NN.
JAMA Dermatol. 2022 Sep 21:e223862. doi: 10.1001/jamadermatol.2022.3862. Online ahead of print.
PMID: 36129688

Thank You to Our Generous 2022 Annual Fall Meeting Supporters

PLATINUM

Sagis, PLLC

GOLD

AbbVie

AEVA Digital

Janssen Biotech, Inc.

UCB, Inc.

SILVER

Leo Pharma, Inc

Mayne Pharma

Organogenesis

Ortho Dermatologics, a division
of Bausch Health, US, LLC

Regeneron (Libtayo

Regeneron/Sanofi Genzyme
(Dupixent)

EXHIBITORS

Almirall

Amgen-IBU

AMLo Biosciences

Arcutis Biotherapeutics

Argenx

Beiersdorf

Biofrontera, Inc

Boehringer-Ingelheim Pharma-
ceuticals

Bristol Myers Squibb

Casio America, Inc

EXHIBITORS (Continued)

Castle Biosciences, Inc

Cockerell Dermatopathology

DermTech

Eli Lilly Pharmaceuticals

Epiphany Dermatology

EUROIMMUN US

Galderma

Genentech BioOncology

Helsinn Therapeutics

Hill Dermaceuticals, Inc

Integrated Dermatology

Krystal Biotech

Mallinckrodt

Medical Pathology Associates

MIMEDX

Mindera Health

Modernizing Medicine

PathAI Diagnostics

Pathology Watch

ProPath

SandsRX Pharmacy

Sensus Healthcare

skinbetter science

SkinCure Oncology

South Texas Dermatopathology

Strata Skin Sciences

Sun Pharma

Novartis Pharmaceuticals

EPI Health

TDS FUTURE PARTNER SUPPORTERS

*Thank you to the following
members who contributed to the
"Future Partner" program*

Kirstin Altman, MD

Thomas Lee Busick, MD

Turner M. Caldwell, III, MD

Conner Chan, MD

Leo A. Conger, Jr., MD

Mara Dacso, MD

Avered Dearl Dotson, MD

Taylor C. Duke, MD

Laura Paul Fite, MD

Bernard R. Gibson, MD

Charles Robert Gobert, MD

Michael S. Graves, MD

Emily C. Grimshaw, MD

Ronald Eugene Grimwood, MD

Catherine Riddel Harrell, MD

Laura Jennifer Haygood, MD, FAAD

Beverly Louise Held, MD

Mary Alice Hickson, MD

Leisa L. Hodges, DO

Chad D. Housewright, MD

Keagan H. Lee, MD

Stephen D. Maberry, MD

Bobbak Mansouri, MD

James Richmond McCarty, MD

Seena Monjazebe, MD

Karla Nicole Munoz, MD

Kehinde Ogunmakin, MD

Sharon Smith Raimor, MD

Lindy S. Ross, MD

Tatiana S. Sousa, MD

Brent Spencer, MD

William E. Tausend, MD

Kien Tran, MD

Gregory D. Walker, MD

Wendi Wohltmann, MD, FAAD